RXRX - Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

• Gain’s cutting-edge precision medicine platform and novel compounds enable therapeutic access to previously undruggable targets.
• Public investors can access this disruptive technology at a venture-like valuation.
• A clean balance sheet funds the business until H2 2023, with multiple value inflections expected.
• Management has a track record of creating value through pharma partnerships and exits.
• Approaching top-line data for lead compound in GBA1 Parkinson’s has game-changing potential.

For further details see: